MA34593B1 - Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral - Google Patents

Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral

Info

Publication number
MA34593B1
MA34593B1 MA35795A MA35795A MA34593B1 MA 34593 B1 MA34593 B1 MA 34593B1 MA 35795 A MA35795 A MA 35795A MA 35795 A MA35795 A MA 35795A MA 34593 B1 MA34593 B1 MA 34593B1
Authority
MA
Morocco
Prior art keywords
substrated
carba
fluoro
nucleoside analogues
antiviral treatment
Prior art date
Application number
MA35795A
Other languages
English (en)
Inventor
Aesop Cho
Choung Kim
Adrian Ray
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34593(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/885,917 external-priority patent/US7973013B2/en
Priority claimed from US13/050,820 external-priority patent/US8455451B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA34593B1 publication Critical patent/MA34593B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nucléosides à imidazo[1,2-f][1,2,4]
MA35795A 2010-09-20 2013-04-04 Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral MA34593B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/885,917 US7973013B2 (en) 2009-09-21 2010-09-20 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US13/050,820 US8455451B2 (en) 2009-09-21 2011-03-17 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PCT/US2011/029441 WO2012039791A1 (fr) 2010-09-20 2011-03-22 Analogues carbanucléosidiques 2'-fluoro-substitués pour traitement antiviral

Publications (1)

Publication Number Publication Date
MA34593B1 true MA34593B1 (fr) 2013-10-02

Family

ID=47748238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35795A MA34593B1 (fr) 2010-09-20 2013-04-04 Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral

Country Status (22)

Country Link
EP (1) EP2619206A1 (fr)
JP (4) JP2013538230A (fr)
KR (1) KR101879887B1 (fr)
CN (1) CN103108876A (fr)
AP (1) AP3699A (fr)
AU (1) AU2011306066B2 (fr)
BR (1) BR112013008017A2 (fr)
CA (1) CA2807496C (fr)
CL (1) CL2013000727A1 (fr)
CO (1) CO6680669A2 (fr)
CR (1) CR20130172A (fr)
EA (1) EA026523B1 (fr)
EC (1) ECSP13012560A (fr)
IL (1) IL225221A0 (fr)
MA (1) MA34593B1 (fr)
MX (1) MX2013003179A (fr)
NZ (1) NZ608070A (fr)
PE (3) PE20171624A1 (fr)
PH (1) PH12013500311B1 (fr)
SG (1) SG188223A1 (fr)
WO (1) WO2012039791A1 (fr)
ZA (1) ZA201301042B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
CN104230985B (zh) * 2014-09-01 2017-01-18 北京天弘天达医药科技有限公司 (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (fr) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprenant un inhibiteur d'arn polymérase et de la cyclodextrine pour le traitement d'infections virales
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (fr) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano
CA3179226A1 (fr) 2020-05-29 2021-12-02 Tomas Cihlar Methodes de traitement par remdesivir
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2023261450A1 (en) * 2022-04-25 2024-11-14 Miracure Biotechnology Limited Nucleoside drug for treating or preventing coronavirus infection, and use thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (fr) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
WO2002057425A2 (fr) * 2001-01-22 2002-07-25 Merck & Co., Inc. Derives de nucleoside comme inhibiteurs de l'arn polymerase virale arn-dependante
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
EP2345657A1 (fr) * 2003-05-30 2011-07-20 Pharmasset, Inc. Analogues de nucléosides fluores modifiés
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (fr) * 2004-10-21 2006-06-22 Merck & Co., Inc. Nucleosides de pyrrolo[2,3-d]pyrimidine fluores destines au traitement d'infections ribovirales dependantes de l'arn
WO2006121820A1 (fr) 2005-05-05 2006-11-16 Valeant Research & Development Promedicaments de phosphoramidate pour traitement d'infections virales
WO2007027248A2 (fr) 2005-05-16 2007-03-08 Valeant Research & Development Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc)
CA2627839C (fr) 2005-11-02 2014-08-19 Bayer Healthcare Ag Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
SI2114980T1 (sl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
EP2125819B1 (fr) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires
CA2685520A1 (fr) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Composes de tetrahydrofuro [3,4-d] dioxolane pour utilisation dans le traitement d'infections virales et de cancer
ES2398684T3 (es) * 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
WO2010036407A2 (fr) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Analogues nucléosidiques antiviraux
EP2313102A2 (fr) * 2008-07-03 2011-04-27 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
NZ594370A (en) * 2009-02-10 2014-01-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
PE20120995A1 (es) * 2009-09-21 2012-08-01 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral

Also Published As

Publication number Publication date
CL2013000727A1 (es) 2013-08-23
EA026523B1 (ru) 2017-04-28
ECSP13012560A (es) 2013-06-28
AU2011306066B2 (en) 2015-01-29
PH12013500311A1 (en) 2013-04-22
MX2013003179A (es) 2013-04-24
BR112013008017A2 (pt) 2016-06-14
KR20130110168A (ko) 2013-10-08
EP2619206A1 (fr) 2013-07-31
PE20131165A1 (es) 2013-10-14
PE20171624A1 (es) 2017-11-02
KR101879887B1 (ko) 2018-07-18
CA2807496C (fr) 2019-01-22
IL225221A0 (en) 2013-06-27
AU2011306066A1 (en) 2013-02-28
PE20230684A1 (es) 2023-04-21
NZ608070A (en) 2015-11-27
CA2807496A1 (fr) 2012-03-29
JP2017119726A (ja) 2017-07-06
JP2019014726A (ja) 2019-01-31
JP2013538230A (ja) 2013-10-10
WO2012039791A1 (fr) 2012-03-29
JP2016074732A (ja) 2016-05-12
PH12013500311B1 (en) 2017-11-08
ZA201301042B (en) 2014-07-30
CR20130172A (es) 2013-05-29
CN103108876A (zh) 2013-05-15
JP6475280B2 (ja) 2019-02-27
AP2013006767A0 (en) 2013-03-31
AP3699A (en) 2016-05-31
CO6680669A2 (es) 2013-05-31
SG188223A1 (en) 2013-04-30
EA201390141A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
MA34593B1 (fr) Analogues de carba-nucleoside subtitues avec le 2'-fluoro pour le traitement antiviral
AP2012006189A0 (en) 2'-fluoro substituted carbanucleoside analogs for antiviral treatment.
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
TW200635938A (en) Fluorosurfactants
EP2780307A4 (fr) Procédé de préparation d'hydrofluorooléfines
MY173521A (en) Trpv4 antagonists
PL2906209T3 (pl) D-metadon do leczenia objawów psychiatrycznych
EP3404032A3 (fr) Procédé de fabrication de composés de benzoxazépine
PH12016500683A1 (en) Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines
IN2014CN04050A (fr)
IN2015DN00515A (fr)
MX2014001623A (es) Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.
MX347541B (es) Analogos de acido sialico.
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
EA201400606A1 (ru) Полиолефиновое волокно
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
MA38701A1 (fr) Fond de poche et poche
FR2961420B1 (fr) Procede d'usinage avec compensation de la dilatation de la piece
MX2015001134A (es) Compuestos terapeuticos.
UA98724C2 (en) 4,3'-spiro[(2-amino-3-cyano-4,5-dihydro[3,2-c]chromene-5-one)-5-methyl-2'-oxindole] as nephroprotective agent
HK1181678A (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
HK1182103A (en) 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
UA70312U (ru) Применение антигельминтика "бровермектин - гранулят тм" как профилактически-лечебного средства при эктопаразитозах карповых рыб
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами